Deferasirox-d4 是标记为 Deferasirox 的氘。 Deferasirox (ICL 670) 是一种口服铁螯合剂,用于治疗输血性铁过载。
Cas No. | 1133425-75-8 |
别名 | 地拉罗司 d4 |
Canonical SMILES | OC(C(C([2H])=C1[2H])=C([2H])C([2H])=C1N2C(C3=C(O)C=CC=C3)=NC(C4=C(O)C=CC=C4)=N2)=O |
分子式 | C21H11D4N3O4 |
分子量 | 377.4 |
溶解度 | DMF: 30 mg/ml,DMSO: 20 mg/ml,Ethanol: 2 mg/ml |
储存条件 | Store at -20°C |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | Deferasirox-d4 is intended for use as an internal standard for the quantification of deferasirox by GC- or LC-MS. Deferasirox is a synthetic, tridentate iron chelator that binds iron at a 2:1 ratio. It is selective for iron (Fe(III)) over Cu(II), Zn(II), Mg(II), and Ca(II) but does bind to Al(III). Deferasirox decreases iron levels in iron-loaded rat heart cells in vitro by 45.8 and 55.6% compared to control levels when used at concentrations of 160 and 320 µM, respectively. In hypertransfused rats, deferasirox (200 mg/kg) decreases radiolabeled liver iron levels from 41 to 21.7% and blood iron levels from 8.2 to 3.4%. It is primarily excreted via the fecal route, in contrast to the iron chelator deferoxamine . Deferasirox also inhibits proliferation of SAS human oral squamous carcinoma cells (EC50 = 21 µM), decreases cyclin D1 protein levels, and increases protein levels of N-Myc downregulated gene 1 (NDRG1) and NDRG3. It acts in a synergistic manner when used in combination with gemcitabine to reduce proliferation of BxPC-3 pancreatic cancer cells in vitro and reduce tumor growth in a BxPC-3 mouse xenograft model when administered at a dose of 200 mg/kg. Formulations containing deferasirox have been used in the treatment of β-thalassemia and chronic iron overload. |